Abatacept in Early Diffuse Cutaneous Systemic Sclerosis – Results of a Phase 2 Investigator‐Initiated, Multicenter, Double‐Blind Randomized Placebo‐Controlled Trial

ConclusionsIn this Phase 2 trial, abatacept was well tolerated, but change in mRSS was not statistically significant. Secondary outcome measures, including gene expression subsets, showed some evidence in favor of abatacept. These data should be confirmed in a Phase 3 trial.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - July 23, 2019 Category: Rheumatology Authors: Dinesh Khanna, Cathie Spino, Sindhu Johnson, Lorinda Chung, Michael Whitfield, Christopher P. Denton, Veronica Berrocal, Jennifer Franks, Bhaven Mehta, Jerry Molitor, Virginia D. Steen, Robert Lafyatis, Robert W. Simms, Anna Gill, Suzanne Ka Tags: Full Length Source Type: research